
Claims


1. A prodrug of a Selective Progesterone Receptor Modulator (SPRM) wherein the SPRM is selected from (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one



(Compound 2)

or a pharmaceutically acceptable salt thereof,

where the Prodrug is (3α,11β,17β)-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-diene-3,17-diol Compound 1



(Compound 1)

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a Prodrug according to claim 1 optionally admixed with a pharmaceutically acceptable excipient or carrier.

3. The Prodrug according to claim 1 for use in therapy and/or as prophylaxis.

4. The Prodrug according to claim 3 for use in treating and/or prophylaxis of gynaecological diseases and symptoms thereof or for fertility control and emergency contraception.

5. The Prodrug according to claim 4 wherein the gynaecological diseases are selected from Uterine Fibroids and Endometriosis and symptoms thereof.

6. A method for obtaining a Prodrug as defined in claim 1, wherein the Prodrug is obtained by a reduction step involving a reducing agent; preferably the reducing agent is sodium borohydride, wherein (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one (Compound 2) is reacted in presence of the reducing agent.

7. The method according to claim 6 wherein the reaction for obtaining the Prodrug is catalyzed by an isolated Aldo-Keto Reductase (AKR) enzyme.

8. A pharmaceutical composition comprising
   - an isolated Cytochrome P450, preferably the Cytochrome P450 is CYP3A4;
   - Prodrug as defined in claim 1; and
   - Optionally admixed with a pharmaceutically acceptable excipient or carrier.

9. An *ex vivo* method for activating the Prodrug as defined in claim 1 by contacting the Prodrug with a Prodrug activating agent, wherein the Prodrug activating agent is an isolated Cytochrome P450, preferably the Cytochrome P450 is CYP3A4.